Which of the following beta-lactam antibitotics can be safely used in a patient with a history of allergy to penicillins?
**Core Concept**
The question is testing the knowledge of cross-reactivity among beta-lactam antibiotics, a critical concept in managing patients with a history of antibiotic allergy. Beta-lactam antibiotics, including penicillins, cephalosporins, and monobactams, share a similar chemical structure, which can lead to cross-reactivity.
**Why the Correct Answer is Right**
The correct answer is a beta-lactam antibiotic that belongs to a different class, making it less likely to cause cross-reactivity with penicillins. Cephalosporins, in particular, have a similar structure to penicillins but are less likely to cause cross-reactivity due to their different side chain structures. This is because the side chain of cephalosporins is more distinct from penicillins, reducing the likelihood of an immune response.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it is another beta-lactam antibiotic that shares a similar structure with penicillins, increasing the risk of cross-reactivity.
* **Option B:** This option is incorrect because it is a beta-lactamase inhibitor, which is not a class of antibiotics and is not typically considered safe for use in patients with penicillin allergy.
* **Option D:** This option is incorrect because it is a carbapenem, a class of beta-lactam antibiotics that is highly cross-reactive with penicillins due to their similar structure.
**Clinical Pearl / High-Yield Fact**
When managing patients with a history of antibiotic allergy, it is essential to consider the cross-reactivity between different classes of beta-lactam antibiotics. A careful assessment of the patient's medical history and a thorough review of the literature are necessary to determine the safest option for treatment.
**Correct Answer: C. Cephalosporins can be safely used in a patient with a history of allergy to penicillins, but it is essential to carefully assess the patient's medical history and cross-reactivity risk.**